Physician profile
Marc A Tack
NPI 1376582015
$49,815.54
in general payments reported to CMS, 2019-2025
51 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $4,308 · 2021: $2,459 · 2022: $1,558 · 2023: $11K · 2024: $4,428 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,643 · Food and Beverage: $5,096 · Travel and Lodging: $4,621 · Education: $34.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,642.50 |
| Food and Beverage | $5,095.66 |
| Travel and Lodging | $4,620.92 |
| Education | $34.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $36,642.46 | 2019-2025 | Arikayce |
| Shionogi INC | $2,963.97 | 2024 | Fetroja |
| Viiv Healthcare Company | $1,914.00 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Gilead Sciences, INC. | $1,276.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,223.21 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Amgen INC. | $696.56 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Abbvie INC. | $670.79 | 2021-2025 | Dalvance, Teflaro, Avycaz |
| Pfizer INC. | $579.43 | 2019-2025 | |
| Horizon Therapeutics Plc | $444.43 | 2019-2023 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $421.42 | 2019-2025 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $411.04 | 2019-2025 | Saphnelo, Evusheld, Airsupra |
| Glaxosmithkline, LLC. | $315.92 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Biotech, INC. | $225.20 | 2019-2025 | Tremfya |
| Exact Sciences Corporation | $201.52 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $172.36 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Tack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.